Pluspunten
Decent pay, middle management didn't hover, honorable product
Minpunten
1. Quality management system needs an update and an overhaul. Document control, procedures, forms, their system is unnecessarily convoluted, vague, and difficult to navigate. Good luck getting trained on it either, everything was self taught and you learned by completing something and having quality tell you you did it wrong.
2. Terrible marketing, low sales, and little to no effort into expanding their market. C suite complained about lack of income and low sales but they were making no effort to onboard additional hospitals and centers, and no effort to train additional surgical teams on the transplant procedure. There will be a cap on the number of hearts you sell if there are only 4 surgeons in the country who can perform the implant.
3. Poor financial decision making. Rather than investing in sales, marketing, and onboarding additional hospitals and surgeons to increase heart sales, the financial priority was working on a replacement product which with delay after delay and how slow development goes on medical devices unfortunately caused them to bleed money even faster and lead to this round of lay-offs (June 2026).